Olivier Morand PhD

Olivier Morand is Senior Director, Clinical Science Program Head, at Actelion Pharmaceuticals Ltd, Allschwil, Switzerland. His focus is on new therapies for rare metabolic diseases. While at Actelion he was also leading the Life Cycle team that successfully ran the Zavesca® program for type 1 Gaucher disease and Niemann-Pick type C disease. Previously he held research positions in Drug Discovery at Roche in Basel, Switzerland and at Merck & Co. in Rahway, NJ (USA). He developed his know-how in several academic institutions such as the University of Wisconsin, Madison, the Hadassah School of Medicine, Jerusalem, and the Mount Sinai School of Medicine, New York. He holds two PhDs in Biochemistry and Nutrition (University of Paris).